# US 2024/0390503 A1 · Green Tea-based Nanocomplexes for Eye Disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0390503 A1
- Document ID: US20240390503A1
- Status: Published application
- Kind: A1
- Application number: 18/690,862
- Filed: 2022-08-31
- Published: 2024-11-28
- Earliest claimed: 2021-09-15
- Assignees: Agency for Science, Technology and Research; Singapore Health Services Pte Ltd
- Applicants: Agency for Science, Technology and Research; Singapore Health Services Pte Ltd
- Inventors: Motoichi Kurisawa; Nunnarpas Yongvongsoontorn; Joo Eun Chung; Yasuo Yanagi
- Web page: https://patentgrep.com/patent/US20240390503A1

## CPC

- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/5161: {Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin}
- A61K 47/541: {Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent}
- A61K 47/61: the organic macromolecular compound being a polysaccharide or a derivative thereof
- A61K 47/6939: {the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin}
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/02: Ophthalmic agents
- A61K 9/148: {with compounds of unknown constitution, e.g. material from plants or animals (with oils, fats, waxes, shellac A61K9/145)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a composition comprising a self-assembled nanocomplex, wherein the self-assembled nanocomplex comprises one or more active agent physically bound to one or more conjugate, wherein each conjugate comprises one or more flavonoid molecule and a first water-soluble polymer, and the nanocomplex is at least partially encapsulated by a second water-soluble polymer. The present invention also relates to a method of preparing the composition and uses thereof. The present invention also relates to a method of treating an eye disease caused by angiogenesis, comprising administering a composition to a subject in need thereof, wherein the composition comprises a self-assembled nanocomplex, wherein the self-assembled nanocomplex comprises an ophthalmic anti-angiogenesis drug physically bound to one or more conjugate, each conjugate comprising one or more flavonoid molecule and a first water-soluble polymer.

## Claims

### Claim 1

A composition comprising a self-assembled nanocomplex, wherein the self-assembled nanocomplex comprises one or more active agent physically bound to one or more conjugate, wherein each conjugate comprises one or more flavonoid molecule and a first water-soluble polymer, and the nanocomplex is at least partially encapsulated by a second water-soluble polymer.

### Claim 2 (depends on 1)

The composition according to claim 1, wherein the flavonoid is selected from the group consisting of (−)-epicatechin, (+)-epicatechin, (−)-catechin, (+)-catechin, (−)-epicatechin gallate, (+)-epicatechin gallate, epigallocatechin, epigallocatechin gallate, fisetinidol, gallocatechin, gallocatechin gallate, mesquitol, robinetinidol, ellagitannin, gallotannin, oolongtheanin, phlorotannin, tannin, theacitrin, theadibenzotropolone, theaflavin, theanaphthoquinone, thearubigins, theasinensin, quercetin, revastrol, rutin, curcumin isorhamnetin, kaempferol, myricetin, fisetin, hesperitin, naringenin, eriodictyol, genistein, daidzein, cyanidin, delphinidin, malvidin, pelargonidin, peonidin, daidzein, genistein, glycitein, biochanin A, formononetin, apigenin, luteolin, baiocalein, chrysin, and any mixture thereof.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The composition according to claim 1, wherein the active agent is a small molecule, a protein or an oligonucleotide.

### Claim 5 (depends on 1)

The composition according to claim 1, wherein the active agent is a therapeutic agent selected from the group consisting of a chemotherapeutic agent, an anti-inflammatory agent, an anti-oxidant agent, an ophthalmic anti-angiogenesis drug, and any combination thereof, or wherein the active agent is present in the range of 0.1 wt % to 90 wt % of the total weight of the composition.

### Claim 6 (depends on 1)

The composition according to claim 1, wherein the first water-soluble polymer is the same as or is different from the second water-soluble polymer.

### Claim 7 (depends on 6)

The composition according to claim 6, wherein the first water-soluble polymer and the second water-soluble polymer are independently selected from the group consisting of glycosaminoglycan, polysaccharide, polyacrylamide, poly(N-isopropylacrylamide), poly(oxazoline), polyethylenimine, poly(acrylic acid), polymethacrylate, poly(ethylene glycol), poly(ethylene oxide), poly(vinyl alcohol), poly(vinylpyrrolidinone), polyether, poly(allylamine), polyanhydride, poly(β-amino ester), poly(butylene succinate), polycaprolactone, polycarbonate, polydioxanone, poly(glycerol), polyglycolic acid, poly(3-hydroxypropionic acid), poly(2-hydroxyethyl methacrylate), poly(N-(2-hydroxypropyl)methacrylamide), polylactic acid, poly(lactic-co-glycolic acid), poly(ortho esters), poly(2-oxazoline), poly(sebacic acid), poly(terephthalate-co-phosphate), hyaluronic acid, alginate, amylose, carrageenan, cellulose, cyclodextrin, dextrin, dextran, ficoll, gelatin, gellan gum, guar gum, heparosan, keratin, pectin, polysucrose, pullulan, scleroglucan, starch, xanthan gum, xyloglucan, chitosan, and any mixture thereof, or any derivative thereof.

### Claim 8 (depends on 1)

The composition according to claim 1, wherein the one or more flavonoid molecule is covalently bound to the first water-soluble polymer.

### Claim 9 (depends on 1)

The composition according to claim 1, wherein the conjugate has the structure depicted by any one of formula (I), (II), or (III):
wherein n and m are independently an integer in the range of 1 to 30,000.

### Claim 10 (depends on 1)

The composition according to claim 1, wherein the conjugate has a molecular weight in the range of 1 kDa to 10,000 kDa.

### Claim 11 (depends on 1)

The composition according to claim 1, wherein the nanocomplex has a hydrodynamic diameter in the range of 10 nm to 5000 nm, a polydispersity index in the range of 0.01 to 0.50, a surface charge in the range of −60 mV to 50 mV, or a drug loading content in the range of 0.1% to 90% by weight of the nanocomplex.

### Claim 12 (depends on 1)

A pharmaceutical composition or a pharmaceutical formulation comprising the composition as defined in claim 1.

### Claim 13 (depends on 1)

A method of forming the composition according to claim 1 comprising the steps of:
a) mixing a solution of an active agent and a solution of a flavonoid-first water-soluble polymer conjugate to form a mixture;
b) adding a second water-soluble polymer to the mixture of step (a) to form a nanocomplex;
wherein steps a) and b) may be performed simultaneously or sequentially, and
c) allowing the nanocomplex of step (b) to self-assemble, wherein the nanocomplex comprises the active agent physically bound to the flavonoid-first water-soluble polymer conjugate that is at least partially encapsulated by the second water-soluble polymer, wherein the flavonoid-first water-soluble polymer conjugate comprises one or more flavonoid molecules and a first water-soluble polymer.

### Claim 14 (depends on 1)

A method of inhibiting endothelial cell proliferation when activated by a proangiogenic growth factor in vitro comprising administering the composition according to claim 1, or a pharmaceutical composition or a pharmaceutical formulation comprising the composition as defined in claim 1.

### Claim 15

(canceled)

### Claim 16 (depends on 1)

A method of treating an eye disease caused by angiogenesis comprising administering a composition according to claim 1, or a pharmaceutical composition or a pharmaceutical formulation comprising the composition as defined in claim 1 to a subject in need thereof.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the composition is administered topically and/or intravitreally to an eye of the subject.

### Claim 18

(canceled)

### Claim 19 (depends on 17)

The method of claim 17, further comprising administering an angiogenesis drug intravitreally to the eye of the subject.

### Claim 20 (depends on 16)

The method according to claim 16, wherein the eye disease is selected from the group consisting of posterior eye disease, age-related macular degeneration, neovascular age-related macular degeneration, diabetic retinopathy, neovascular glaucoma, diabetic macular oedema, retinal vascular occlusion, and corneal neovascularization.

### Claim 21 (depends on 16)

The method according to claim 16, wherein the composition is in liquid form or solution form.

### Claim 22 (depends on 1)

The method according to claim 1, wherein the composition is administered once daily, twice daily, thrice daily, once weekly, once fortnightly, once monthly, once every 2 months, once every 3 months, once every 4 months, once every 5 months, once every 6 months, once every 9 months, or once every 12 months.

### Claim at position 23

-24. (canceled)

### Claim 25

A method of treating an eye disease caused by angiogenesis, comprising administering a composition to a subject in need thereof, wherein the composition comprises a self-assembled nanocomplex, wherein the self-assembled nanocomplex comprises an ophthalmic anti-angiogenesis drug physically bound to one or more conjugate, each conjugate comprising one or more flavonoid molecule and a first water-soluble polymer.

### Claim at position 25

-27. (canceled)
